Athenex (ATNX) Stock Price, News & Analysis

Company Overview

Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapies for the treatment of cancer. It operates through the Oncology Innovation Platform and Commercial Platform segments. The Oncology Innovation Platform segment focuses on the research and development of proprietary drugs. The Commercial Platform segment covers the sale and market of specialty drugs and market development of proprietary drugs. The company was founded by Lyn M. Dyster and David G. Hangauer in November 2003 and is headquartered in Buffalo, NY.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.20 to $1.52
• 52-Week Range: N/A
• Volume: 1.88 million shs
• Average Volume: 194,316 shs
• Market Capitalization: $1.76 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Athenex Stock Analysis - MarketRank™

Athenex scored higher than 3% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Athenex.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Athenex is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Athenex is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ATNX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Athenex does not currently pay a dividend.

Dividend Growth

Athenex does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.1 / 5
• Environmental Score: -1.97

Short Interest

There is no current short interest data available for ATNX.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

12 people have searched for ATNX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Athenex insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.20% of the stock of Athenex is held by insiders.

Percentage Held by Institutions

Only 30.48% of the stock of Athenex is held by institutions.

ATNX Stock Analysis - Frequently Asked Questions

How were Athenex's earnings last quarter?

Athenex, Inc. (NASDAQ:ATNX) posted its earnings results on Thursday, November, 4th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.08. The company had revenue of $32.30 million for the quarter, compared to analyst estimates of $19.40 million. Athenex had a negative trailing twelve-month return on equity of 727.79% and a negative net margin of 86.31%.

When did Athenex IPO?

Athenex (ATNX) raised $72 million in an IPO on Wednesday, June 14th 2017. The company issued 6,000,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Deutsche, Bank Securities and J.P. Morgan served as the underwriters for the IPO and ICBC International was co-manager.

What other stocks do shareholders of Athenex own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Athenex investors own include TherapeuticsMD (TXMD), Meta Platforms (META), Sorrento Therapeutics (SRNE), NIO (NIO), NVIDIA (NVDA), Tesla (TSLA) and Ford Motor (F).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 11/02/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ATNX
• CUSIP: N/A
• CIK: 1300699
• Web: www.athenex.com
• Phone: (716) 427-2950
• Fax: N/A
• Employees: 652
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($15.88)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-103,430,000.00
• Net Margins: -86.31%
• Pretax Margin: -95.92%
• Return on Equity: -727.79%
• Return on Assets: -44.44%

Debt

• Debt-to-Equity Ratio: 3.08
• Current Ratio: 1.09
• Quick Ratio: 0.72

Sales & Book Value

• Annual Sales: $102.82 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($3.07) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 8,660,000
• Free Float: 7,866,000
• Market Cap: $1.76 million
• Optionable: Optionable
• Beta: 1.36